REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-26. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Besides being a physical barrier, the sulcular epithelium is able to release antimicrobial peptides which retard the growth of bacteria.This is through the secretion of defensins (β-defensins (hBD-1 and hBD-2)) which are a unique feature of the sulcular epithelium as compared to the junctional epithelium. However if plaque build-up occurs due to the lack of proper oral hygiene practices, bacteria are able to adhere to the sulcular epithelium using their fimbriae. It is discovered that the biofilm adhered to the sulcular epithelium consists of a rich content of glycocalyces, suggesting that these virulence factors allow the survival and colonisation of the periodontal pathogens. The fimbriae then induces the inflammatory response via the release of proinflammatory cytokines, leading to bone resorption. During periodontal disease, the epithelial barrier of the sulcular epithelium becomes discontinuous or ulcerated, compromising the integrity of these junctional complexes. This results in an increase in epithelial permeability and facilitates the passage of bacterial products. This is further promoted through the non-keratinised nature of the epithelium which also acts as a semi-permeable membrane. The transport of harmful bacterial products into the gingiva allows the detection of bacteria action which allows the sulcular epithelium to retaliate through the diffusion of the gingival crevicular fluid (GCF) containing inflammatory cells (neutrophils & small lymphocytes) & inflammatory mediators (IL-8, CXCL8 chemokines) into the sulcus.
Lemna Ecotox testing Duckweed growth inhibition tests and standardisation OECD Guideline for Lemna Test Archived 2016-01-07 at the Wayback Machine USDA Plants Profile: North American Species Jepson Manual Treatment: Lemna
The biosynthetic gene clusters encoding the biological machinery responsible for producing enediynes have been cloned and characterized for five 9-membered enediynes (C-1027, neocarzinostatin, maduropeptin, sporolides, and kedarcidin), and three 10-membered enediynes (calicheamicin, esperamicin, and dynemicin). Comparative studies of these biosynthetic apparatus have shown that the enediyne core of these molecules is initiated by a common enzyme, enediyne polyketide synthase (PKS). The polyene product of this enzyme is then divergently elaborated into the 9- or 10-membered cores of the enediynes depending on the specific PKS-associated enzymes present. A convergent biosynthetic strategy is then employed by the producing organisms, whereby the varying peripheral appendages of the enediynes are attached to the core structure to furnish the final product. In 2013, the successful cloning and characterization of the kedarcidin biosynthetic cluster ("ked") was reported by researchers at the Scripps Research Institute and the University of Wisconsin-Madison. The identity of this cloned gene cluster was corroborated by kedA, a gene in the cluster that encodes the previously isolated kedarcidin apoprotein, as well as kedE and kedE10, the co-expression of which in E. coli led to the formation of a signature heptaene product previously implicated in enediyne core biosynthesis.
Sources: en.wikipedia.org
== Awards == In 2009, Amana Contracting and Steel Buildings was awarded the Dubai Quality Appreciation Program certificate for the construction field. In 2014, the company was awarded the CSR Label by The Dubai Chamber of Commerce and Industry.
== External links == P. Romano, C. Fiore, M. Paraggio, M. Caruso, A. Capece "Function of yeast species and strains in wine flavour". Archived 2015-06-06 at the Wayback Machine. International Journal of Food Microbiology 86 (2003). pp. 169–180.
and likewise for angles B, C, with equality in the first part if the triangle is isosceles and the apex angle is at least 60° and equality in the second part if and only if the triangle is isosceles with apex angle no greater than 60°. Further, any two angle measures A and B opposite sides a and b respectively are related according to
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.